Foghorn Therapeutics announces 2023 annual meeting results; all director nominees elected and auditor ratified

Foghorn Therapeutics Inc.

Douglas Cole elected with 19,470,509 for, 2,142,125 against; Gill elected with 21,481,572 for, 144,160 against.
Parshall elected with 21,600,133 for, 25,599 against; there were 9,648,103 broker non-votes on director election.
Ratification of Deloitte & Touche as auditor passed with 31,282,179 for, 858 against, 9,849 abstentions.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Foghorn Therapeutics Inc. shareholders approved Election of three Class III directors at the 2023-06-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

Director Nominee Votes For Votes Against Abstentions Douglas G. Cole, M.D. 19,470,509 2,142,125 32,149 Balkrishan (Simba) Gill, Ph.D. 21,481,572 144,160 19,051 B. Lynne Parshall 21,600,133 25,599 19,051 There were 9,648,103 broker non-votes regarding the election of directors.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Foghorn Therapeutics Inc. shareholders approved Ratification of selection of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-21

Exact text from the filing

Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting included 31,282,179 votes for, 858 votes against and 9,849 abstentions. There were no broker non-votes regarding this proposal.

View on SEC.gov

Browse all shareholder votes →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-023124

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.